Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
- 1 June 2005
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 23 (3) , 263-269
- https://doi.org/10.1007/s10637-005-6736-x
Abstract
Aprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-α. This study aimed to evaluate the response rate to combination therapy with aprinocarsen, gemcitabine and cisplatin, in chemonaive patients with advanced/metastatic NSCLC. Secondary objectives included comparison of response rate, time to event efficacy parameters, and toxicities on the 2 treatment arms. Patients with stage IV, or stage IIIB disease (N3 and/or pleural/pericardial effusion), were randomized to either control or experimental arm. Patients on both arms received gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 80 mg/m2 on day 1 of a 3-week cycle. Additionally, on the experimental arm, aprinocarsen was administered as 2 mg/kg continuous iv infusion on days 1–14, every 21 days. A total of 18 enrolled patients were randomized on the 2 arms. Further enrollment was terminated in March 2003 as a result of a phase III trial suggesting that aprinocarsen did not have an added survival benefit when combined with paclitaxel and carboplatin therapy in patients with NSCLC. Patients received a median of 4 cycles on control arm and 2.5 cycles on experimental arm. The response rate was 16.7% in the experimental arm and 44.4% in the control arm. Most frequent grade 3/4 toxicities were hematologic, with a higher incidence of thrombocytopenia in the experimental arm (87.5% vs. 33.3%). Despite the 14-day continuous infusion schedule, infection rate was not increased in the experimental arm. The present study did not show any advantage, in response rate or secondary endpoints, with aprinocarsen; however, the toxicity was not unduly increased, and aprinocarsen regimen was safely administered.Keywords
This publication has 18 references indexed in Scilit:
- Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancerAnnals of Oncology, 2004
- State-of-the-art treatment for advanced non-small-cell lung cancer.2003
- Targeting Protein Kinase C‐alpha (PKC‐α) in Cancer with the Phosphorothioate Antisense Oligonucleotide AprinocarsenAnnals of the New York Academy of Sciences, 2003
- O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLCLung Cancer, 2003
- P-194 Meta-analysis of infection during continuous infusion chemotherapy with minimal infusate changesLung Cancer, 2003
- Antisense Oligonucleotides in the Treatment of Non–Small-Cell Lung CancerClinical Lung Cancer, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Antisense therapy in oncology: new hope for an old idea?The Lancet, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- The potential of protein kinase C as A target for anticancer treatmentPharmacology & Therapeutics, 1993